Biotech Startups
9,603 companies tagged Biotech, with their investors and founders.
Ark applies machine learning and AI to bioprocessing, replacing trial-and-error methods with hybrid predictive models to accelerate drug development and scale biotherapeutic manufacturing. The platform serves biopharmaceutical companies and biotech firms seeking to reduce R&D timelines and production costs.
4 investors
ARS Pharma develops needle-free epinephrine treatments, including neffy, an FDA-approved epinephrine nasal spray for patients and caregivers managing allergic reactions. The company focuses on providing portable, easy-to-use alternatives to needle-based epinephrine delivery.
4 investors
Arsenale builds an end-to-end biomanufacturing platform that combines micro-scale bioreactors, AI software, and large-scale fermentation infrastructure for precision fermentation at industrial scale. The system spans organism design in the lab to industrial production, targeting bio-based production of food, materials, and goods.
4 investors
Artiva Biotherapeutics is a clinical-stage biotechnology company developing natural killer (NK) cell-based therapies for patients with autoimmune diseases. Its lead candidate, AlloNK, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in clinical trials in combination with B-cell targeted monoclonal antibodies for conditions such as rheumatoid arthritis and SjΓΆgren's disease.
4 investors
Angelini Pharma Switzerland is the Swiss arm of a pharmaceutical company focused on brain health and epilepsy, offering prescription treatments for patients and healthcare professionals. Its Swiss portfolio includes the antiepileptic medication Ontozry (cenobamate).
4 investors
Astrivax develops virus-targeted immunotherapies using its Launch-iT platform to eliminate cancer-causing viruses before they lead to disease, with an initial focus on HPV-driven cancers. The company targets an oncology therapeutic space for people at risk of virus-driven cancers.
4 investors
Atalanta develops RNA interference-based therapeutics aimed at treating central nervous system and neurological diseases. The company applies its founders' discoveries in RNAi to target diseases at their genetic source.
4 investors
Atara Biotherapeutics develops allogeneic T-cell immunotherapies using its proprietary EBV T-cell platform to harness the immune system for treating disease. The company focuses on next-generation cell-based therapies designed for patients worldwide.
4 investors
Atavistik Bio is a clinical-stage biotechnology company developing allosteric small-molecule therapeutics that selectively modulate disease-causing proteins. Its pipeline includes ATV-1601, an oral AKT1-selective inhibitor for Hereditary Hemorrhagic Telangiectasia, and a JAK2V617F mutant-selective inhibitor for myeloproliferative neoplasms.
4 investors
Atelerix develops hypothermic hydrogel encapsulation technology that stabilises and preserves fresh cells, tissues, and blood at room temperature, eliminating the need for cryopreservation and cold-chain logistics. Its plant-based, xeno-free kits (such as CytoStor, BeadReady, and STORganoid) serve research and clinical labs shipping live cell material, organoids, and 3D cell models.
4 investors
Atrandi builds single-cell analysis technology based on Semi-Permeable Capsules (SPCs) and droplet platforms, enabling multi-step, multi-omic workflows to be run on the same cell. It serves research laboratories working on applications such as co-sequencing, microbial genomics, and single-cell screening workflows.
4 investors
4 investors
Auransa is a clinical-stage, AI-native biopharma company that analyzes large human disease datasets to discover and develop novel cancer therapies. It works collaboratively with pharmaceutical companies and academic institutions to advance its drug discovery programs.
4 investors
Avant develops cultivated animal protein as an alternative to wild-caught fish, aiming to produce seafood protein without contaminants such as heavy metals, microplastics, and parasites. The company operates in the cultivated/cell-based foodtech space and is building pilot production capacity.
4 investors
AvenCell Therapeutics develops next-generation cell therapies for hard-to-treat cancers, including solid tumors, combining switchable universal CAR-T technology with a CRISPR/Cas9-based allogeneic platform. The clinical-stage biopharmaceutical company creates autologous and allogeneic reprogrammable T-cell products and operates in both the US and Europe.
4 investors
Averna Therapeutics is a biotechnology company developing therapeutics. The page is a team bio profiling its CEO and board member.
4 investors
New gene therapy treatments for people with serious, rare diseases. (NASDAQ: BOLD) (Acquired by Astellas)
4 investors
Avidicure develops "Actibody", a triple-agonistic antibody platform built on a human IgG scaffold designed to activate the innate and adaptive immune system for treating oncology and autoimmune diseases. Its lead program, AVC-S-201, is a Ξ³Ξ΄ T cell-targeting antibody being developed for AML and other blood cancers and solid tumors.
4 investors
Avilar develops ATACs (ASGPR Targeting Chimeras), a class of protein degraders designed to target extracellular and membrane-bound proteins by harnessing the endolysosome's natural degradation process. The company applies its drug discovery platform to create degraders as potential treatments for serious diseases.
4 investors
AVTTX is a clinical-stage company developing gene therapy treatments for retinal and ophthalmologic diseases. The company leverages adeno-associated virus (AAV) technology to address unmet medical needs in vision care.
4 investors
Axi.om uses agentic intelligence and AI to predict, explain, and fix drug toxicity early in development by leveraging the largest experimental-to-clinical dataset of profiled molecules linked to human clinical outcomes.
4 investors
Axiom Therapeutics runs a drug discovery platform for covalent inhibitors, applying machine learning to speed up physics-based simulations. The work is aimed at oncology research teams pursuing targets that have been difficult to drug.
4 investors
Azafaros is a clinical-stage biopharmaceutical company developing nizubaglustat, an orally available azasugar with a dual mode of action targeting the central nervous system and glycosphingolipid metabolism. Its lead candidate is being evaluated in a Phase 3 study for treating patients with GM1/GM2 gangliosidoses and related rare lysosomal storage disorders.
4 investors
Barnwell Bio runs a biosurveillance platform that analyzes environmental samples such as waste streams to detect pathogen trends and provide animal health data. It serves livestock and poultry producers and veterinarians, offering data to guide disease management and evaluate feed additives, vaccines, and biosecurity protocols.
4 investors